Purpose:
Despite the high infectivity of Mycobacterium tuberculosis (Mtb), only 5-10% of infected individuals develop clinical symptoms and radiological evidence of active disease [1] . Also, clinical presentation in patients with active tuberculosis (TB) varies substantially from mild symptoms to severe or fatal TB, the former being characterized by an in ltrative-exudative pulmonary lesion and the latter by large, cavitary lung lesions or miliary TB.
Cell-mediated immunity represents the main component of host defense against Mtb [2] ; the T-helper 1 ( 1) immune response, which is characterized by the production of IL-12, TNF-α and IFN-γ [3] [4] [5] [6] , implies a close interplay between CD4+ T-cells and macrophages and is usually able to control bacterial proliferation and to prevent TB clinical progression. In particular, IFN-γ, produced by CD4+ T-cells, plays a key role in the host response to Mtb, given its activating e ect on macrophages is responsible for the intracellular killing of mycobacteria [7, 8] . Recent studies have focused on a new CD4+ T-cell subset, 17 cells, as an important mediator of immune responses against Mtb [9] . 17 cells produce IL-17, a potent proin ammatory cytokine that has been implicated in many autoimmune and in ammatory diseases, including rheumatoid arthritis, multiple sclerosis, asthma and systemic lupus erythematosus [10, 11] . Generation of human 17 cells depends on IL-23, IL-1β, TGF-β and IL-6 stimulation [12] [13] [14] . In the lungs, IL-17 triggers neutrophil chemotaxis and induces the production of chemokines, growth factors and adhesion molecules [15] . e IL-23-IL17 axis has recently been shown to participate in the immune response to Mtb [16] [17] [18] [19] . Both in vitro and in vi o experiments have shown defective TH1 and TH17 response in patients with TB in comparison with healthy tuberculin reactors, and a negative correlation between IFN-γand IL-17 levels and disease severity [14, 16, [21] [22] [23] [24] . A clear-cut shi towards TH2 immune response has been demonstrated [25] ; in fact, increased levels of IL-4, the prototypical TH2 cytokine, as well as IL-5 and IL-10, have been found in patients with TB and have been related to a more severe clinical state [26] [27] [28] . Other studies have reported opposing results, describing higher levels of IL-17-producing CD4+ T cells among subjects with active TB and a direct correlation between the frequency of IL-17 secreting cells and disease severity [29] [30] [31] .
In the present study, IFN-γ and IL-17 levels were determined in the supernatant of peripheral blood mononuclear cells (PBMCs) isolated from patients with di erent clinical and radiological features of pulmonary TB and stimulated in vitro with puri ed protein derivative (PPD). IFN-γ and IL-17 expression pro les for patients with pulmonary TB were compared with those of a group of tuberculin-negative and tuberculin-reactive healthy controls.
Materials and Methods

Study subjects
Fi y-two consecutive patients with pulmonary TB, diagnosed at the Unit of Infectious Diseases of Catania, Eastern Sicily, Italy, were enrolled for the study between January 2010 and January 2012; diagnosis was based on clinical history, chest Xray, intradermal tuberculin PPD test and positive detection of acid-fast bacilli in sputum smear or isolation of mycobacteria in sputum cultures. All patients with a positive sputum culture for mycobacteria also had molecular characterization of Mtb as determined by polymerase chain reaction (PCR). On the basis of speci c clinical and radiological features, patients were divided into four subgroups as follows: 1), patients with in ltrative TB (n=17); 2), patients with cavitary TB (n=15); 3),patients with miliary TB (n=10); and 4),patients with chronic brous TB (n=10). Subgroup 1: Cases of in ltrative TB were characterized by radiological evidence of apical exudative in ltration without micro-or macronodules or cavitations.
Subgroup 2: Patients with cavitary TB had single unilateral (n=8) or multiple bilateral (n=7) lung cavities.
Subgroup 3: Patients with miliary TB were de ned on the basis of the presence of widespread micronodules (<2 mm) on chest CT scan, with or without extrapulmonary involvement (2 out of 10 miliary cases had a concurrent meningeal disease).
Subgroup 4: Radiological evidence of lung brotic bands and/or pleural calci cations associated with a history of previous untreated or incorrectly treated TB, with repeated positive sputum smears throughout a period of at least 72 months, was consistent with the diagnosis of chronic brous TB.
Blood samples were taken from all TB patients at diagnosis, within two days of hospital admission and before starting antitubercular treatment.
e control group consisted of 30 healthy subjects, 15 of whom were PPD-positive and 15 were PPD-negative. Participants had not been vaccinated with BCG, were serologically negative for HIV infection and had no known condition associated with overt immune depression, such as steroid or other immunosuppressive drug intake, cancer or onco-haematological disease, primitive immune de ciency, chronic or acute renal failure, or poorly controlled diabetes.
Written informed consent was obtained from patients and control subjects for blood sampling and PPD skin test.
e main clinical and epidemiological characteristics of the study populationare shown in Table 1 .
Cell preparation and in vitro cultures
Heparinized peripheral blood, drawn from patients and healthy controls, was diluted 1:4 with PBS, overlayed on FicollHypaque (Sigma, Milan, Italy) and centrifuged at 1600 rpm for 20 minutes. e mononuclear cell layer was then removed from the plasma/Ficoll interface, washed twice with PBS and resuspended in Roswell Park Memorial Institute (RPMI) 1640 medium, supplemented with fetal calf serum (10%), penicillin/ streptomycin (1%) and L-glutamine (1%). Cells were plated in 24-well tissue culture plates (Falcon) and incubated with or without PPD (1 μg/mL, Biocine PPD lio lo, Sclavo, Siena, Italy) for 72 hours, at 37ºC in a 5% CO2 humidi ed atmosphere. A er 72-hour incubation, supernatants were collected, centrifuged and stored frozen (-20ºC) until use.
Enzyme linked immunosorbent assay (ELISA) for human IFN-γ and IL-17
IL-17 concentration in cell supernatant was measured using a solid-phase enzyme ampli ed sensitivity immunoassay performed on microtiter plate, purchased from Biosource Europe S.A. (Biosource IL-17 Cytoscreen kit, Nivelles, Belgium), following the manufacturer's instructions. e lower limit of detection of the assay was 2 pg/ml. IFN-γ concentration in cell supernatant was measured by ELISA (Predicta, Genzyme Diagnostics, Cambridge, USA). e lower limit of detection for the assay was 3 pg/mL.
Statistics
Data were expressed as means ± standard deviation (SD). Categorical variables were analyzed by using the Fisher's exact test. Intergroup comparisons were performed using by the paired and unpaired Student's t test. Statistical analysis was performed using Prism so ware (GraphPad, La Jolla, USA).
Results
IFN-γ and IL-17 levels in the supernatant of PPD-stimulated PBMCs from patients with di erent patterns of pulmonary TB and healthy controls were analyzed.
Baseline and post-PPD levels of IL-17
Baseline levels of IL-17 were signi cantly lower among patients with TB in comparison with healthy controls (205 ± 57 vs 75 ± 11 pg/mL, p=0.05). Mean IL-17 concentration a er PPDstimulation was 153 ± 88 pg/mL in TB patients, which was again signi cantly less (p=0.043) than in healthy controls. After PPD stimulation, a signi cant rise from basal IL-17 values was found among healthy controls (p=0.02), whereas in patients with TB no signi cant increase was seen in comparison with baseline values (Figure 1a c. IL-17 levels in the supernatant of peripheral blood mononuclear ce nary TB (n=52), divided into four groups on the basis of their clinical protein derivative). Baseline (*p<0.01) and post-PPD levels (**p<0.01) other groups; in addition, post-PPD levels were signi cantly higher inpa (n=15), miliary (n=10) and chronic brous (n=10) TB (***p<0.01). A tients with in ltrative (α p<0.01), cavitary (β p=0.048) and chronic br ells (PBMCs) from patients with TB (n=52) and healthy controls d protein derivative). Baseline levels were signi cantly higher in healthy t rise in IL-17 levels was found only in healthy controls (**p=0.02). controls in comparison with patients with TB (*p=0.043).
ells (PBMCs) from healthy controls whose tuberculin skin test was n IL-17 levels was found in tuberculin-negative (*p=0.05), as well as ost-PPD values.
ells (PBMCs) from healthy controls (n=30) and patients with pulmol state, at baseline and a er 72-hour stimulation with PPD (puri ed were signi cantly higher in healthy controls in comparison with the atients with in ltrative TB (n=17), compared with those with cavitary er PPD stimulation, a signi cant rise in IL-17 levels was found in paous (γ p=0.038) TB, but not in patients with miliary TB. b. IFN-γ levels in the supernatant of peripheral blood mononuclear ce positive (n=15) and negative (n=15) at enrolment. A signi cant rise in (*p<0.01). Post-PPD levels were signi cantly higher among tuberculin (**p<0.01)
c. IFN-γ levels in the supernatant of peripheral blood mononuclear ce monary TB (n=52), divided into four groups on the basis of their clin ed protein derivative). Baseline levels were similar. Post-PPD levels we other groups (*p<0.01). Patients with cavitary (n=8), miliary (n=5) and whereas signi cant di erences were observed for patients with in ltrativ ells (PBMCs) from patients with TB (n=52) and healthy controls d protein derivative). A signi cant rise in IFN-γ levels was observed in IFN-γ production was signi cantly higher in controls, in comparison ells (PBMCs) from healthy controls whose tuberculin skin test was n IFN-γ levels was detected only in tuberculin-reactive subjects reactive subjects, in comparison with tuberculin negative patients ells (PBMCs) from healthy controls (n=30) and patients with pulnical state, at baseline and a er 72-hour stimulation with PPD (puriere higher among patients with in ltrative TB in comparison with the d chronic (n=5) TB did not show a signi cant increase in IFN-γ levels, ve (n=7) TB (**p<0.01). tion varied signi cantly among patients with di erent TB clinical features. In fact, patients with miliary TB did not exhibit a signi cant increase in IL-17 production a er PPD stimulation (61 ± 7 vs 71 ± 38 pg/mL); in contrast, IL-17 levels rose signi cantly a er PPD stimulation among those subjects with in ltrative TB (87 ± 13 vs 350 ± 99 pg/mL, p<0.01), cavitary TB (51 ± 10 vs 132±78 pg/mL, p=0.048) and chronic brous TB (81 ± 10 vs. 178 ± 68 pg/mL, p=0.032) (Figure 1c) .
Among healthy controls, baseline and PPD-induced IL-17 did not signi cantly di er between tuberculin-reactive and tuberculin-negative subjects. A er PPD challenge, IL-17 levels signi cantly rose from baseline both in tuberculin-negative (p=0.05) and in tuberculin-reactive (p<0.01) subjects ( Figure  1b ).
Baseline and post-PPD levels of IFN-γ
At baseline, IFN-γ levels were similar between healthy controls and patients with TB; a er PPD stimulation, a signi cant increase in IFN-γ levels was observed for both TB patients (from 19.6 ± 9.4 pg/ml to 121.8 ± 159.1 pg/ml, p<0.01) and healthy controls (from 17.8 ± 6.3 pg/ml to 205.5 ± 85.8 pg/ml, p<0.01) (Figure 2a) . In detail, IFN-γ concentration in PBMCs supernatants was signi cantly higher a er PPD-stimulation in tuberculin-reactive controls in comparison with those tuberculin-negative patients whose levels did not rise signicantly from baseline (Figure 2b) . When considering only the TB cohort, subgroup analysis showed a signi cant increase in IFN-γ levels among patients with in ltrative TB (p<0.01). In contrast, PPD stimulated-PBMCs from patients with chronic, miliary and cavitary TB did not produce higher levels of IFN-γ in comparison with unstimulated PBMCs (Figure 2c) .
Discussion
In the present study, PBMCs from patients with TB were found to release a signi cantly lower amount of IL-17 than PBMCs from healthy controls; moreover, our ndings support the existence of a clear-cut correlation between IL-17 levels and clinical presentation of pulmonary TB. In fact, in patients with in ltrative TB, usually considered as the clinical prototype of a strong but pathologic cell-mediated response to Mtb (mostly described among young and immunocompetent adults [4] ), a consistently higher production of PPD-induced IL-17 was seen in comparison with other clinical forms of pulmonary TB, such as cavitary and miliary TB, but not in comparison to healthy controls. In addition, a signi cantly higher production of IFN-γ was observed in subjects with in ltrative disease, when compared with healthy controls and subjects with other clinical features of TB, in keeping with the major role of 1 cytokines during the host response to Mtb [8] .
It is well known that a switch from 1 to 2 cell response takes place in clinically overt TB. Some recent studies suggested a role for impaired 17 response in determining the severity of pulmonary TB. Chen et al. [18] reported the 17 response to be suppressed in patients with active TB: ow cytometry analysis showed that the frequency of a nonspeci c 17 response was signi cantly lower in patients with active TB disease than in healthy controls and subjects with latent TB infection (LTBI) and, of importance, suppressed 17 response correlated with the severity of disease since those patients with pulmonary TB exhibiting meningeal complications had a signi cantly lower frequency of 17 cells than patients with uncomplicated pulmonary TB. Kumar et al. [22] found similar results in a population of children a ected with active TB: children with TB had diminished 1 and 17 cytokine responses in comparison with controls, either spontaneously in vitro or following PBMCs stimulation with mycobacterial antigens. In addition, children with active TB complicated by microbial dissemination and neurological involvement showed the most profound defect in production of both IFN-γ and IL-17. Stern et al. [32] reported a 9-fold increase in the levels of IL-17 mRNA a er PPD stimulation of PBMCs drawn from individuals with LTBI. Consistent with the results of the present study, Scriba et al. [16] reported a reduced Mtb-speci c 17 response in patients with active TB in comparison with healthy donors. Other authors reported opposing results: Jurado et al. [29] recently demonstrated that in patients a ected with TB, stimulation of lymphocytes with sonicated Mtb antigens induced a signi cantly lower amount of IFN-γ and higher concentration of IL-17 than healthy controls. e authors showed that IL-17 was secreted by CD4+ IFN-γ+ IL-17+ lymphocytes, whose proportion directly correlated with the severity of disease. Similarly, Marin et al. [30] reported that patients with active TB had a higher frequency of circulating IL-17-producing CD4+ T cells a er PPD stimulation than subjects with LTBI. In contrast to the results of the present study, Sargentini et al. [33] did not observe any signi cant difference in IL-17 release from PBMCs between healthy controls and patients with active TB a er 72-hour stimulation with PPD; however, in this study, a very limited number of individuals (14 patients and 6 controls) was enrolled. In a recent paper of Cowan et al. [34] , the authors found that the frequency of IL-17-producing CD4+ T cells was lower in patients with active TB in comparison with healthy controls and subjects with LTBI. A er a 7-day stimulation of PBMCs with my-cobacterial antigens, Cowan and coworkers detected a signicant higher increase in IL-17-expressing CD4+ T cells among patients with active TB, in comparison with healthy controls. In contrast with our observation of similar response to PPD stimulation among tuberculin-negative and tuberculin-reactive subjects, Babu et al. [35] found that the production of 17 cytokines, such as IL-17 and IL-23, was signi cantly lower in tuberculin-reactive individuals a er challenging with PPD and Mtb culture ltrate.
Our study has a number of limitations: rstly, it was conducted on a relatively small number of patients. Secondly, since PPD, which is not a Mtb speci c antigen, was used to stimulate PBMCs, further research is required to establish whether our ndings may be reproduced when stimulating PBMCs with speci c Mtb antigens, such as ESAT-6 and CFP-10. irdly, cytokine production was measured by ELISA so further evaluation by using surface and intracellular cytokine ow cytometry should be worthwhile. In addition, it would be interesting to focus on the possible role of macrophages and dendritic cells, considering that their interaction with Mtb antigens and their subsequent cytokine secretion may modulate host response to Mtb [36] .
In conclusion, IL-17 production is inhibited in patients with pulmonary TB, with particular reference to cavitary or miliary TB, both of which are characterized by a weaker cellmediated immune response.
e protective and pathological mechanisms of immune response to Mtb are complex and still unclear. More research is needed to understand how 17 cytokines may in uence the severity of TB presentation. Further investigations are required in order to shed light on the complex network of cytokine responses that mediate resistance or susceptibility to Mtb infection and determine the variability of clinical presentation of pulmonary TB.
